#OncSky #regulatory #bcsm
📣 #FDA has approved trastuzumab deruxtecan + pertuzumab for 1st-line tx of adults w/ HER2+ unresectable or #MetastaticBreastCancer based on DB-09 trial:
🏆44% ⬇️ in risk of progression/death vs THP (mPFS: 40.7 vs 26.9 mos).
⚠️ ILD ~12%
Google drugs@FDA for current label